Crinetics Pharmaceuticals (CRNX)

Executive Summary

Crinetics Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering oral small-molecule therapies for rare endocrine diseases, leveraging its proprietary GPCR-targeted platform. Its lead candidate, paltusotine (PALSONIFY™), is in Phase 3 development for acromegaly, with two ongoing studies (NCT05192382 and NCT04837040) expected to support regulatory submissions. Paltusotine has demonstrated efficacy in reducing IGF-1 levels in prior trials, offering a once-daily oral alternative to injectable somatostatin analogs. Beyond acromegaly, Crinetics is evaluating paltusotine in a Phase 2 trial for carcinoid syndrome (completed) and advancing a pipeline including atumelnant (CRN04894), a novel ACTH antagonist in Phase 1/2 for Cushing syndrome (NCT05804669), and CRN09682, a somatostatin receptor type 2 (SST2) agonist in Phase 1/2 for neuroendocrine tumors (NCT07129252). With a robust cash position and a focus on high-value orphan indications, Crinetics is well-positioned to transform endocrine disease treatment. Key near-term catalysts include paltusotine Phase 3 data readouts and potential NDA submission, along with initial efficacy signals from atumelnant and CRN09682.

Upcoming Catalysts (preview)

• H2 2026Paltusotine Phase 3 Acromegaly Top-Line Results85% success
• Q4 2026Atumelnant Phase 1/2 Cushing Syndrome Data60% success
• 2027CRN09682 Phase 1/2 Neuroendocrine Tumor Initial Data40% success